文献速递甲状腺疾病骨质疏松与钙磷/甲状旁腺

65岁以上成人因Graves病行全甲状腺切除术后需骨化三醇治疗的永久性甲状旁腺功能减退风险:一项基于人群的队列研究

Risk of Permanent Hypoparathyroidism Requiring Calcitriol Therapy in a Population-Based Cohort of Adults Older Than 65 Undergoing Total Thyroidectomy for Graves' Disease.
PubMed 文献 · Thyroid · 2022-12-15

该研究利用2007至2017年美国Medicare数据库,纳入4650例65岁以上因Graves病行全甲状腺切除术的患者,评估术后需骨化三醇治疗的永久性甲状旁腺功能减退发生率。结果显示104例(2.2%,95%CI 1.8-2.7%)发生该结局,多因素回归中仅年龄≥76岁与风险相关(OR=1.68,95%CI 1.13-2.51)。作者认为风险较低,不应成为合适老年手术候选者的阻碍。

要点

  • 65岁以上Graves病全甲状腺切除术后永久性甲状旁腺功能减退需骨化三醇治疗的发生率为2.2%(95%CI 1.8-2.7%)。
  • 年龄≥76岁较66-75岁与永久性甲状旁腺功能减退风险相关(OR=1.68,95%CI 1.13-2.51)。
  • 作者认为该风险不应成为合适老年手术候选者行手术治疗的阻碍。

核心结论

  • 在该美国全国性基于人群的老年Graves病全甲状腺切除队列中,需骨化三醇治疗的永久性甲状旁腺功能减退风险较低,即使手术由heterogeneous组外科医生完成。
  • 这些发现提示,对于适合手术的老年Graves病患者,甲状旁腺功能减退风险不应成为手术治疗的阻碍。

研究设计与样本

  • 基于人群的队列研究,使用2007至2017年100% Medicare索赔数据,纳入65岁以上因Graves病行全甲状腺切除术且术前无甲状腺癌诊断、未长期术前使用骨化三醇的患者。
  • 要求手术前后各12个月连续参加Medicare Parts A、B和D,最终纳入4650例患者(平均年龄72.8岁,标准差5.5;86%女性;79%白人)。

主要发现

  • 4650例患者中,104例(2.2%,95%CI 1.8-2.7%)发生需骨化三醇治疗的永久性甲状旁腺功能减退。
  • 发生永久性甲状旁腺功能减退者平均年龄较未发生者更高(74.1岁 vs 72.8岁,p=0.04)。
  • 多因素回归中,年龄≥76岁较66-75岁与永久性甲状旁腺功能减退相关(OR=1.68,95%CI 1.13-2.51),为唯一与结局相关的患者特征。

关键数值与推荐

  • 永久性甲状旁腺功能减退定义为甲状腺切除术后6至12个月期间持续使用骨化三醇。
  • 多因素logistic回归纳入年龄、性别、种族/族裔、社区劣势、Charlson-Deyo共病指数、城乡居住地和衰弱。

临床怎么用

  • 作者认为,对于适合手术的老年Graves病患者,甲状旁腺功能减退风险不应成为手术管理的阻碍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: Total thyroidectomy for Graves' disease (GD) is associated with rapid treatment of hyperthyroidism and low recurrence rates. However, it carries the risk of surgical complications including permanent hypoparathyroidism, which contributes to long-term impaired quality of life. The objective of this study was to determine the incidence of permanent hypoparathyroidism requiring calcitriol therapy among a population-based cohort of older adults undergoing total thyroidectomy for GD in the United States. Methods: We performed a population-based cohort study using 100% Medicare claims from beneficiaries older than 65 years with GD who underwent total thyroidectomy from 2007 to 2017. We required continuous enrollment in Medicare Parts A, B, and D for 12 months before and after surgery to ensure access to comprehensive claims data. Patients were excluded if they had a preoperative diagnosis of thyroid cancer or were on long-term preoperative calcitriol. Our primary outcome was permanent hypoparathyroidism, which was identified based on persistent use of calcitriol between 6 and 12 months following thyroidectomy. We used multivariable logistic regression to identify characteristics associated with permanent hypoparathyroidism, including patient age, sex, race/ethnicity, neighborhood disadvantage, Charlson-Deyo Comorbidity Index, urban or rural residence, and frailty. Results: We identified 4650 patients who underwent total thyroidectomy for GD during the study period and met the inclusion criteria (mean age = 72.8 years [standard deviation = 5.5], 86% female, and 79% white). Among this surgical cohort, 104 (2.2% [95% confidence interval, CI = 1.8-2.7%]) patients developed permanent hypoparathyroidism requiring calcitriol therapy. Patients who developed permanent hypoparathyroidism were on average older (mean age 74.1 vs. 72.8 years) than those who did not develop permanent hypoparathyroidism (p = 0.04). On multivariable regression, older age was the only patient characteristic associated with permanent hypoparathyroidism (odds ratio age ≥76 years = 1.68 [CI = 1.13-2.51] compared with age 66-75 years). Conclusions: The risk of permanent hypoparathyroidism requiring calcitriol therapy among this national, U.S. population-based cohort of older adults with GD treated with total thyroidectomy was low, even when considering operations performed by a heterogeneous group of surgeons. These findings suggest that the risk of hypoparathyroidism should not be a deterrent to operative management for GD in older adults who are appropriate surgical candidates.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Seib CD, Meng T, Cisco RM, et al. Risk of Permanent Hypoparathyroidism Requiring Calcitriol Therapy in a Population-Based Cohort of Adults Older Than 65 Undergoing Total Thyroidectomy for Graves' Disease. Thyroid. 2022. PMID: 36416252. doi:10.1089/thy.2022.0140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。